Empowering Dialysis Technicians: Sonavex Makes Ultrasound Easier and Safer

About this Event

According to the CDC, more than 35 million people in the US have Chronic Kidney Disease. When it’s time for dialysis, the quicker they can transition from dangerous central venous catheters to AV fistulas, the less chance there is for infection and mortality, and the more costs are reduced.

Sonavex, a spin out from Johns Hopkins University, has developed a new ultrasound system that is designed to reduce reliance on catheters and associated hospitalizations from several months to several weeks. EchoMark is an implantable, ultrasound visible, bioresorbable polymeric marker placed underneath the fistula that interfaces with EchoSure, a cloud-connected, AI-enabled, 3D automated ultrasound to enable dialysis technicians to collect vascular-lab quality ultrasounds in the clinic without ultrasound training. This solution can be used to improve arteriovenous fistula (AVF) maturation times for dialysis patients.

EchoMark and EchoSure have been clinically validated in a recent multi-center U.S. IDE study. They have received FDA clearances and a CPT code has been awarded. Sonavex is now pursuing AVF-specific indications with its clinical trials. The market for this initial solution alone is $1.8B. A pipeline product leveraging this platform technology is targeting a $5.4B market. Sonavex has received several million dollars in NIH grants and is backed by both VCs and Family Offices.

Watch the webinar with Sonavex CEO, David Narrow, to hear how the company’s game-changing solution is transforming chronic kidney care.

Video On Demand

– Recorded

February 29


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.